Adjunctive fluoxetine improves global function in chronic schizophrenia.
Eight chronic schizophrenic inpatients received adjunctive fluoxetine (20 mg/day) for a mean of 10.6 weeks in an open clinical trial. Clinical state improved in all patients. Violent incidents decreased, while participation in programs and socialization increased.